GPT and hepatocellular carcinoma: HCC risk per ‘treatment grey zone’ group compared with HBV DNA <2000 IU/mL and ALT ≤ ULN group:HBV DNA < 2000 IU/mL and ALT 1–2× ULN: HR = 4.07 (95% CI 1.92–8.64); p < 0.001HBV DNA <2000 IU/mL and ALT ≥ 2× ULN: HR = 5.12 (95% CI 1.97–13.32); p = 0.001HBV DNA 2000–<20,000 IU/mL and ALT ≤ ULN: HR = 2.27 (95% CI 1.16–4.46); p = 0.017HBV DNA 2000–<20,000 IU/mL and ALT 1–2× ULN: HR = 6.69 (95% CI 2.95–15.20); p < 0.001HBV DNA ≥20,000 IU/mL and ALT ≤ULN: HR = 5.18 (95% CI 2.80–9.59); p < 0.001